Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $16.19, but opened at $16.86. Teva Pharmaceutical Industries shares last traded at $16.14, with a volume of 3,642,344 shares trading hands.
Analyst Ratings Changes
TEVA has been the topic of a number of analyst reports. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Finally, Bank of America increased their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and an average price target of $23.71.
Read Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Stock Performance
The company has a fifty day moving average price of $15.18 and a two-hundred day moving average price of $17.46. The firm has a market cap of $19.21 billion, a price-to-earnings ratio of -11.68, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter last year, the firm posted $0.48 EPS. The business's revenue for the quarter was up 1.9% on a year-over-year basis. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
Several large investors have recently modified their holdings of the stock. FMR LLC boosted its position in shares of Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares in the last quarter. Ion Asset Management Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the fourth quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock valued at $807,766,000 after acquiring an additional 409,778 shares during the period. Lingotto Investment Management LLP lifted its position in shares of Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after acquiring an additional 688,862 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in Teva Pharmaceutical Industries by 1.2% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock worth $404,775,000 after purchasing an additional 300,000 shares during the period. 54.05% of the stock is owned by institutional investors.
Teva Pharmaceutical Industries Company Profile
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Articles
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
